Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice
Authors:
- Mikkel Bo BrentMBMikkel Bo Brent
- Frederik Eriksen StoltenborgFSFrederik Eriksen Stoltenborg
- Annemarie BrüelABAnnemarie Brüel
- Jesper Skovhus ThomsenJTJesper Skovhus Thomsen
Open Access
- 19 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Abstract
Three bone anabolic pharmaceuticals are currently approved for treatment of osteoporosis, teriparatide (PTH (1–34)), the parathyroid hormone-related protein analog abaloparatide (ABL), and romosozumab. The present study compared the effect of intermittent PTH (1–34) and ABL on bone tissue directly mole-to-mole in female mice. Forty-seven C57BL/6 mice were randomly allocated to the following groups: Baseline (n = 11), Control (Ctrl) (n = 12), PTH (n = 12), and ABL (n = 12). The mice were injected s.c. with PTH (100 µg/kg), ABL (96 µg/kg), or saline (Ctrl) five days a week for three weeks. To assess the effect of PTH and ABL, the hindlimb bones were analyzed with DXA, µCT, mechanical testing, dynamic bone histomorphometry, and histological quantification of bone cells. In addition, serum calcium concentration was determined. PTH and ABL significantly increased femoral areal bone mineral density (aBMD) (borderline significant p = 0.06 for PTH), femoral mid-diaphyseal bone strength, femoral metaphyseal and epiphyseal and vertebral bone volume fraction (BV/TV), connectivity density, volumetric bone mineral density (vBMD), and bone formation rate (BFR/BS) compared to Ctrl. In addition, ABL also significantly increased mid-diaphyseal cortical thickness and bone area compared to Ctrl. Neither PTH nor ABL significantly increased bone strength at the femoral neck. In conclusion, abaloparatide and PTH have similar bone anabolic properties when compared directly mole-to-mole in mice.Keywords
This publication has 39 references indexed in Scilit:
- Fragility fractures in Europe: burden, management and opportunitiesArchives of Osteoporosis, 2020
- OsteoporosisThe Lancet, 2019
- Osteoporosis treatment: recent developments and ongoing challengesThe Lancet Diabetes & Endocrinology, 2017
- PTH receptor-1 signalling—mechanistic insights and therapeutic prospectsNature Reviews Endocrinology, 2015
- Bone disease in primary hyperparathyrodismTherapeutic Advances in Musculoskeletal Disease, 2012
- Osteoporosis: now and the futureThe Lancet, 2011
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of OsteoporosisBasic & Clinical Pharmacology & Toxicology, 2004
- Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of OsteoporosisTreatments in Endocrinology, 2002
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001